Small molecules targeting ataxia telangiectasia and rad3-related (ATR) kinase: an emerging way to enhance existing cancer therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F16%3A43875578" target="_blank" >RIV/60162694:G44__/16:43875578 - isvavai.cz</a>
Alternative codes found
RIV/68378050:_____/16:00473034 RIV/00179906:_____/16:10323267
Result on the web
<a href="http://www.eurekaselect.com/139285/article" target="_blank" >http://www.eurekaselect.com/139285/article</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/156800961603160206122927" target="_blank" >10.2174/156800961603160206122927</a>
Alternative languages
Result language
angličtina
Original language name
Small molecules targeting ataxia telangiectasia and rad3-related (ATR) kinase: an emerging way to enhance existing cancer therapy
Original language description
he main aim of current cancer research is to find a way to selectively affect the tumor cells, while leaving normal cells intact. Ataxia telangiectasia and Rad3-related kinase (ATR), a member of the phosphatidylinositol-3-related protein kinases (PIKK), represents a candidate target for achieving this goal. ATR kinase is one of the main kinases of the DNA damage response signaling pathway and responds to DNA damage caused by replication stress and various genotoxic agents (i.e. chemotherapy, ionizing radiation, ultraviolet light). ATR activation triggers cell cycle checkpoints, DNA repair and apoptosis, but also resistance of tumor cells to DNA damaging agents, through stress support under replication stress. Thus, the inhibition of ATR leads to increased effectiveness of cancer therapy and in addition enables highly selective targeting of cancer cells through synthetic lethal interactions. Despite this great potential, only a few potent and selective inhibitors of ATR kinase have been developed to date. However, those which have been developed provide great promise, and are under evaluation in many current preclinical and clinical trials. The purpose of this review is to summarize the potential of ATR inhibitors and the medicinal chemistry efforts which resulted in their identification.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Cancer Drug Targets
ISSN
1568-0096
e-ISSN
—
Volume of the periodical
16
Issue of the periodical within the volume
3
Country of publishing house
AE - UNITED ARAB EMIRATES
Number of pages
9
Pages from-to
200-208
UT code for WoS article
000373449300001
EID of the result in the Scopus database
—